Score Overview
Explore the 2021 public Archive ranking →
Where Dr. Reddy’s Laboratories Ltd ADR has ranked, year by year
Showing 5 years ranking history by HDB Score.
Reached the top 50 on HDB Score in 2 years, the longest run being 2 in a row — but not in 2020.
- RDY
2007: 65.7% · 2020: 65.1% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 12.85 | — |
1 Year2025-09-29 | $ 13.83 | -7.09% |
5 Years2021-09-29 | $ 11.46 | 12.11% |
10 Years2016-09-29 | $ 7.47 | 71.96% |
20 Years2006-09-29 | $ 2.36 | 443.62% |
All Time2001-04-11 | $ 0.72 | 17x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2001-04-11 |
|---|---|---|---|---|---|---|
| Price | $ 12.85 | $ 13.83 | $ 11.46 | $ 7.47 | $ 2.36 | $ 0.72 |
| Return | — | -7.09% | 12.11% | 71.96% | 443.62% | 17x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in INR
| Year | |||
|---|---|---|---|
| TTM | ₹ 332.83B | ₹ 33.16B | ₹ 81.42B |
| 2026 | ₹ 353.47B | ₹ 45.08B | ₹ 86.07B |
| 2025 | ₹ 325.53B | ₹ 56.54B | ₹ 57.90B |
| 2024 | ₹ 279.16B | ₹ 55.68B | ₹ 81.47B |
| 2023 | ₹ 245.87B | ₹ 45.06B | ₹ 61.79B |
| 2022 | ₹ 214.39B | ₹ 23.56B | ₹ 44.36B |
| 2021 | ₹ 2.55B | ₹ 472M | |
| 2020 | ₹ 174.60B | ₹ 19.49B | ₹ 340M |
| 2019 | ₹ 153.85B | ₹ 18.79B | ₹ 24.75B |
| 2018 | ₹ 142.02B | ₹ 9.80B | ₹ 20.96B |
| 2017 | ₹ 140.80B | ₹ 12.03B | ₹ 18.13B |
| 2016 | ₹ 154.70B | ₹ 20.01B | ₹ 39.95B |
| 2015 | ₹ 148.18B | ₹ 22.17B | ₹ 39.65B |
| 2014 | ₹ 132.17B | ₹ 21.51B | ₹ 33.53B |
| 2013 | ₹ 116.26B | ₹ 16.77B | ₹ 220.99B |
| 2012 | ₹ 96.73B | ₹ 14.26B | ₹ 18.15B |
| 2011 | ₹ 74.69B | ₹ 11.04B | ₹ 5.76B |
| 2010 | ₹ 70.27B | ₹ 1.06B | ₹ 10.75B |
| 2009 | ₹ 69.44B | -₹ 5.16B | ₹ 6.12B |
| 2008 | ₹ 50.00B | ₹ 4.67B | ₹ 12.15B |
| 2007 | ₹ 65.24B | ₹ 9.34B | ₹ 18.03B |
| 2006 | ₹ 24.32B | ₹ 1.63B | |
| 2005 | ₹ 19.47B | ₹ 211M | ₹ 9.59B |
| 2004 | ₹ 20.12B | ₹ 2.47B | ₹ 6.92B |
| 2003 | ₹ 18.01B | ₹ 3.52B | ₹ 7.25B |
| 2002 | ₹ 16.60B | ₹ 4.91B | ₹ 5.10B |
Dr. Reddy’s Laboratories Ltd ADR fundamental performance
Between 2021 and 2026, revenue grew from ₹ 2.55B to ₹ 353.47B. Revenue increased in 4 of those 5 years; net income in 3.
Across Dr. Reddy’s Laboratories Ltd ADR's full reported history, from 2002 to 2026, revenue grew from ₹ 16.60B to ₹ 353.47B and net income grew from ₹ 4.91B to ₹ 45.08B. Revenue increased in 80% of the years measured; net income in 57%.
Dr. Reddy’s Laboratories Ltd ADR currently holds a 20-year HDB Score of 6.0 out of 10. How the HDB Score is calculated.
Membership
Continue RDY’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
